Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Null cell immunoregulation in SLE.

H A Stephens, P Fitzharris, R A Knight

    Journal of Clinical & Laboratory Immunology
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction: p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis.

    Oncogene·2025
    Same author

    Improvements to the characterization of Agfa x-ray film for use on opacity spectroscopy diagnostics.

    The Review of scientific instruments·2024
    Same author

    Testing the optical components for the National Ignition Facility time-resolved soft x-ray opacity spectrometer (OpSpecTR).

    The Review of scientific instruments·2024
    Same author

    Sub-keV design for the National Ignition Facility's soft x-ray Opacity Spectrometer (OpSpec) and expansion plans for time-resolved measurements.

    The Review of scientific instruments·2022
    Same author

    Characterization of Agfa Structurix series D4 and D3sc x-ray films in the 0.7-4.6 keV energy range.

    The Review of scientific instruments·2021
    Same author

    Upgrades and redesign of the National Ignition Facility's soft x-ray opacity spectrometer (OpSpec).

    The Review of scientific instruments·2021
    Same journal

    Policy and science of FMD control: the stakeholders' contribution to decision making. A call for integrated animal disease management.

    Journal of clinical & laboratory immunology·2006
    Same journal

    An informative case of Graves' disease with implications for schizophrenia.

    Journal of clinical & laboratory immunology·2006
    Same journal

    Increase of circulating CD8+CD57+ lymphocytes after measles infection but not after measles vaccination.

    Journal of clinical & laboratory immunology·2006
    Same journal

    Review: immunomodulatory activity of pregnancy-associated plasma protein-A.

    Journal of clinical & laboratory immunology·2004
    Same journal

    Antibodies to Acinetobacter bacteria and bovine brain peptides, measured in bovine spongiform encephalopathy (BSE) in an attempt to develop an ante-mortem test.

    Journal of clinical & laboratory immunology·2004
    Same journal

    Principles of autoimmune disease: pathogenesis, genetics and specific immunotherapy.

    Journal of clinical & laboratory immunology·2004
    See all related articles

    Normal null cells activate T cells to kill cancer cells. In Systemic Lupus Erythematosus (SLE) patients, this activation is impaired, suggesting abnormal null cell function in SLE.

    Area of Science:

    • Immunology
    • Cellular Biology
    • Autoimmune Diseases

    Background:

    • T cells are crucial for immune responses.
    • Null cells, a type of immune cell, play a role in regulating T cell activity.
    • Dysfunctional immune cells are implicated in autoimmune diseases like Systemic Lupus Erythematosus (SLE).

    Purpose of the Study:

    • To investigate the function of null cells in activating T cells.
    • To determine if null cell function is altered in patients with Systemic Lupus Erythematosus (SLE).

    Main Methods:

    • Normal T cells and null cells were co-cultured with MDA-157 cancer cells.
    • Null cells were activated and then co-cultured with normal T cells.
    • Cytotoxicity and suppressor activity of T cells were measured.

    Related Experiment Videos

  • This process was repeated using activated null cells from SLE patients and disease controls.

    • Main Results:

    • Activated normal null cells induced T cell-mediated cytotoxicity and suppression against MDA-157 cells.
    • Activated null cells from a majority of Systemic Lupus Erythematosus (SLE) patients induced little to no T cell cytotoxicity or suppression.
    • Null cells from disease control populations did not show this impairment.

    Conclusions:

    • Normal null cells can activate T cells to mount an immune response against cancer cells.
    • Null cell function appears to be abnormal in Systemic Lupus Erythematosus (SLE) patients.
    • These findings suggest a potential role for null cell dysfunction in the pathogenesis of SLE.